quinazolines has been researched along with Chromosome Deletion in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heldermon, CD; Kitada, K; Koyama, M; Meacham, AM; Pacak, CA; Santostefano, KE; Tachibana, D; Terada, N; Waldrop, SM; Watanabe, N; Yokoyama, A | 1 |
| Barchuk, AS; Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Levchenko, EV; Matsko, DE; Mitiushkina, NV; Moiseyenko, FV; Moiseyenko, VM; Procenko, SA; Semionov, II; Togo, AV | 1 |
2 other study(ies) available for quinazolines and Chromosome Deletion
| Article | Year |
|---|---|
Generation of Induced Pluripotent Stem Cells from a Female Patient with a Xq27.3-q28 Deletion to Establish Disease Models and Identify Therapies.
Topics: Cell Differentiation; Cells, Cultured; Child, Preschool; Chromosome Deletion; Chromosomes, Human, X; Decitabine; Developmental Disabilities; Female; Fragile X Mental Retardation Protein; Fragile X Syndrome; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Induced Pluripotent Stem Cells; Intellectual Disability; Quinazolines | 2020 |
High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Russia; Treatment Outcome | 2010 |